COMMUNIQUÉS West-GlobeNewswire

TG Therapeutics Announces Phase I Study of Novel BTK inhibitor, TG-1701, in Patients with Relapsed or Refractory B-cell Malignancies is Open for Enrollment
13/11/2018
First dose cohort fully enrolled First patient enrolled with relapsed/refractory Mantle Cell Lymphoma achieved Partial Response (PR) to lowest dose being tested NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- TG [...]
Innovation Pharmaceuticals Presenting Brilacidin for Inflammatory Bowel Disease at “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation
13/11/2018
BEVERLY, Mass., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the Company is presenting a scientific [...]
Tetra Bio-Pharma Promotes Steeve Néron to Senior Vice President, Marketing & Medical Affairs
13/11/2018
Tetra Clarifies Estimated Fair Market Value of North Bud Farms Shares ORLEANS, Ontario, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Tetra Bio-Pharma Inc ., a leader in cannabinoid-based drug discovery and development (TSX VENTURE [...]
KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder
13/11/2018
KP879 is being developed with serdexmethylphenidate, KemPharm’s prodrug of d-methylphenidate, to address a critical unmet need in the treatment of problematic stimulant abuse CELEBRATION, Fla., Nov. 13, 2018 (GLOBE [...]
Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights
13/11/2018
Completed enrollment in Phase 2 study of NYX-2925, top-line data anticipated in the first half of 1Q 2019 Reported demonstration of NYX-2925 pharmacodynamic activity in humans Plan to announce data from interim analysis [...]
U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX® (teduglutide [rDNA origin]) for Children with Short Bowel Syndrome
13/11/2018
Intended for U.S. Audience U.S. FDA Accepts for Filing Shire’s Supplemental New Drug Application for GATTEX ® (teduglutide [rDNA origin]) for Children with Short Bowel Syndrome Seeking approval for the potential use of [...]
MediWound Reports Third Quarter 2018 Financial Results
13/11/2018
Awarded additional BARDA contract valued up to $43 Million for the development of NexoBrid ® for sulfur mustard injuries Conference call begins today at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 13, 2018 (GLOBE [...]
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease
13/11/2018
Planning Phase II Trial VANCOUVER, British Columbia, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH ) (CNSX: BTH ) (FRANKFURT: BTI) (OTCQB: [...]
VBL Therapeutics to Report Third Quarter 2018 Financial Results on November 20
13/11/2018
TEL AVIV, Israel, Nov. 13, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for [...]
Optinose Reports Third Quarter 2018 Financial Results and Recent Operational Highlights
13/11/2018
Company reports third quarter net XHANCE revenue of $1.9 million Company reports 42% monthly XHANCE prescription growth from August to October Conference call and webcast to be held today at 8:00 a.m. Eastern Time [...]
BeiGene Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
13/11/2018
CAMBRIDGE, Mass., and BEIJING, China, Nov. 13, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
How Sentara Healthcare is Removing Boundaries through PACS Modernization with Client Outlook and Mach7
13/11/2018
WATERLOO, Ontario, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Client Outlook Inc. and Mach7 Technologies (Mach7) announced today they have been selected to spearhead Sentara Healthcare’s PACS Modernization project. This [...]
Aravive Presents Detailed Results of Phase 1 Clinical Trial of AVB-S6-500 at the 2018 EORTC-NCI-AACR Symposium
13/11/2018
HOUSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced detailed results of its first-in-human Phase 1 clinical trial of AVB-S6-500 in healthy [...]
RedHill Biopharma Reports Third Quarter 2018 Financial Results and Business Highlights
13/11/2018
Key Highlights: Top-line results from the confirmatory Phase III study with TALICIA ® for H. pylori infection are on track to be announced by year-end 2018, with potential NDA filing in early 2019 Positive top-line [...]
Cybrexa Therapeutics Presents Preclinical Data Demonstrating its alphalex™ Tumor Targeting Platform Delivers a High Dose of PARP Inhibitor in Combination with Chemotherapy
13/11/2018
Synergistic combination selectively kills tumors and prevents bone marrow toxicities Poster presentation today during 30 th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium Marks initial introduction [...]
Cerecor Reports Third Quarter 2018 Results
13/11/2018
BALTIMORE, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (“Cerecor” or the “Company”) (NASDAQ: CERC), a fully integrated biopharmaceutical company with commercial operations and research and development capabilities, [...]
Aran Biomedical Pioneers breakthrough medical textiles valve covering technology; ValvTEX™
13/11/2018
GALWAY, Ireland, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Aran Biomedical, a trusted partner in design, development and manufacture of implantable medical devices, today announced its new medical textile valve covering [...]
AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update
13/11/2018
Announced important clinical milestones for ACI-24 vaccine in Alzheimer's disease and Down Syndrome Company record high, period end cash position of approximately CHF 200 million that is expected to extend our cash [...]
LIDDS receives approval from MPA to start Phase I study NZ-DTX-001
13/11/2018
The Swedish Medical Product Agency has approved a first-in-human study, NZ-DTX-001, in which solid tumors will be treated with NanoZolid combined with docetaxel. This is LIDDS' second clinical project and will initially [...]

Pages